RxDoctor Payments Data

Michelle Brooks

Nurse Practitioner · Tampa, FLNPI 1588062467

Payments from drug & device makers

$1,410in general payments, 2019–2025

Across 65 payments — averaging $21.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$678
  • Viiv Healthcare Company$334
  • Theratechnologies Inc.$132
  • Johnson & Johnson$79
  • Janssen Scientific Affairs, LLC$72
  • Amgen$22
  • plus $94 from 5 others

What the payments were for

  • Food & beverage$1,410100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,410 in reported general payments places this provider in the 75th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$2,081
Medicare patients
16
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala230$932,288
DovatoDolutegravir Sodium/Lamivudine204$604,537
JulucaDolutegravir/Rilpivirine120$414,913
GenvoyaElviteg/Cob/Emtri/Tenof Alafen87$336,460
TivicayDolutegravir Sodium131$302,463
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf47$216,883
CabenuvaCabotegravir/Rilpivirine26$176,922
TrogarzoIbalizumab-Uiyk13$142,869
OdefseyEmtricitab/Rilpiviri/Tenof Ala34$133,441
DescovyEmtricitabine/Tenofov Alafenam55$117,185
TriumeqAbacavir/Dolutegravir/Lamivudi23$85,305
PrezcobixDarunavir/Cobicistat34$81,976
IsentressRaltegravir Potassium28$53,157
Darunavir36$35,454
Etravirine12$11,684

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Cabenuva, Triumeq$334$1,584,139504 claims
GileadBiktarvy, Genvoya, Descovy$678$1,385,933372 claims
Theratechnologies Inc.Trogarzo$132$142,86913 claims
Johnson & JohnsonPrezcobix$79$81,97634 claims
MerckIsentress$21$53,15728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →